How is non‑muscle‑invasive bladder cancer (NMIBC) risk stratified?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

NMIBC Risk Stratification

Non-muscle-invasive bladder cancer (NMIBC) is risk stratified into three primary categories—low-risk, intermediate-risk (IR), and high-risk—based on clinical and pathologic factors, with the International Bladder Cancer Group (IBCG) providing the most current and validated approach for IR-NMIBC substratification using five specific risk factors. 1

Primary Risk Categories

NMIBC encompasses tumors staged as:

  • Ta: Papillary tumors confined to epithelial mucosa
  • T1: Tumors invading lamina propria
  • Tis (CIS): Carcinoma in situ

The fundamental stratification divides patients into low-risk, intermediate-risk, and high-risk groups based on tumor characteristics including stage, grade, size, multifocality, and recurrence history. 2

IBCG Intermediate-Risk Substratification (2025)

For IR-NMIBC specifically, the IBCG model uses five clinical risk factors to further substratify patients into three prognostic subgroups 1:

The Five IBCG Risk Factors:

  1. Multifocality (multiple tumors)
  2. Tumor size (>3 cm)
  3. Early recurrence (recurrence within 1 year)
  4. Recurrence rate (>1 recurrence per year)
  5. Prior intravesical therapy failure

IBCG IR-NMIBC Substratification:

  • IR-low (0 factors): Comparable to low-risk disease; 3-year recurrence ~12%, progression ~1%
  • IR-intermediate (1-2 factors): Moderate risk; 3-year recurrence ~38%, progression ~3%
  • IR-high (≥3 factors): Highest IR subgroup; 3-year recurrence ~77%, progression ~7%; 5-year progression 17%, recurrence 78%

This stratification has been externally validated in 2,822 patients and demonstrates stepwise increases in both recurrence and progression across risk groups. 3

Alternative Risk Stratification Tools

EORTC Risk Tables

The 2006 European Organization for Research and Treatment of Cancer (EORTC) risk tables remain the most widely used and validated tools globally, incorporating:

  • Number of tumors
  • Tumor size
  • Prior recurrence rate
  • T category
  • Presence of CIS
  • Tumor grade

Important caveat: The EORTC tables overestimate recurrence and progression risks in patients treated according to current guidelines, as they were developed before modern treatment standards. 4

EAU Risk Categories

The European Association of Urology provides simplified risk categories that serve as an alternative to EORTC tables for comparable risk stratification. 5, 4

CUETO Scoring Model

For patients treated with short maintenance BCG schedules, the Club Urológico Español de Tratamiento Oncológico (CUETO) model is more accurate than EORTC tables. However, like EORTC, it also overestimates risks under current treatment paradigms. 4

Clinical Application

The choice of risk stratification system matters for specific outcomes 6:

  • NCCN classification: Best discriminative performance for predicting intravesical recurrence
  • EAU classification: Significantly associated with grade progression from low-grade to high-grade disease
  • All systems: Predict progression from Ta to ≥T1, but none adequately stratify progression from T1 to T2

Simplified Three-Factor Model

Recent validation suggests that three factors capture most prognostic signal in IR-NMIBC without loss of discrimination 7:

  1. Multifocality
  2. Early recurrence
  3. Failure of intravesical therapy

This simplified approach maintains comparable discriminative performance while reducing complexity.

Key Pathologic Considerations

Risk stratification requires complete pathologic assessment including 2:

  • Presence of lamina propria and muscularis propria in specimen
  • Degree of invasion
  • Lymphovascular invasion (LVI): Associated with worse prognosis and should be documented
  • Tumor grade (low-grade vs high-grade)

Common Pitfalls

  • Incomplete initial resection: Compromises accurate staging and risk assessment
  • Missing muscularis propria: Prevents definitive T1 diagnosis; requires repeat resection
  • Applying outdated risk models: EORTC and CUETO overestimate risks with modern treatment
  • Ignoring IR-NMIBC heterogeneity: Treating all IR patients identically leads to over- or under-treatment

The IBCG five-factor model represents the most current, validated approach for IR-NMIBC substratification and should guide treatment intensity decisions, particularly regarding intravesical therapy selection and surveillance protocols. 1, 3

References

Related Questions

How is risk stratification performed in non‑muscle‑invasive bladder cancer and what are the recommended management and surveillance strategies for low‑, intermediate‑, and high‑risk disease?
In a bladder tumor with invasive high‑grade papillary urothelial carcinoma that invades the lamina propria above the muscularis mucosa, and where muscularis propria (detrusor muscle) was not sampled, is this considered minimally T1 disease?
What are the recommended intravesical chemotherapy regimens and schedules for non‑muscle‑invasive bladder cancer (Ta, T1, or carcinoma in situ)?
What are the recommendations of the European Association of Urology (EAU) guidelines 2026 for managing urological diseases, such as prostate cancer, bladder cancer, kidney stones, and urinary tract infections?
In which urothelial cancers is BCG (Bacillus Calmette-Guérin) indicated?
If ketorolac and tramadol are ineffective for renal colic pain, what short‑acting opioid analgesic should be given?
What are the differential diagnoses for osteomyelitis?
What intravenous iron regimen is recommended for a first-trimester pregnant patient with a ferritin of 4 ng/mL?
How should a patient with epiretinal membrane and vitreous hemorrhage be managed?
In a pregnant patient with iron‑deficiency anemia, how should ferumoxytol (Feraheme) be used, including appropriate dosing, timing, and safety considerations compared with other IV iron formulations?
For a patient with an estimated glomerular filtration rate of 44 mL/min/1.73 m², what is the appropriate initial dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.